Allergan plc, of Dublin, and Gedeon Richter plc, of Budapest, Hungary, said the FDA approved Vraylar (cariprazine) capsules, an atypical antipsychotic, for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for treatment of schizophrenia in adults.